Abstract
Infections of skin and soft tissue (SSTIs) encompass a diverse set of conditions, but there are commonalities that justify their consideration as a group. Some SSTIs are not dangerous to the patient, whereas others are life threatening and require radical surgical debridement as well as broad-spectrum antibiotic therapy. The U.S. Food and Drug Administration (FDA) classified SSTIs as uncomplicated or complicated infections for the purposes of clinical trial design and enrollment. This framework is also useful for clinical description.1
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
